By Puyaan Singh Aug 6 (Reuters) - Eye drugmaker Tarsus Pharmaceuticals said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding ...

Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.

How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its second quarter 2026 financial ...

CEO Bobak Azamian highlighted the exceptional performance of XDEMVY, stating, "We delivered more than 103,000 bottles of XDEMVY to patients and recognized approximately $119 million in net revenue." ...

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified ...

Tarsus Pharmaceuticals, Inc. (TARS) now has an approved product called XDEMVY, which is rapidly capturing the Demodex blepharitis market. The strong commercial launch is increasingly supporting ...

Tarsus is gearing up for a potential FDA green light of its experimental drug to treat a common but little-known eyelid inflammation disease and is wasting no time to boost awareness around the ...

A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US. Tarsus Pharmaceuticals' Xdemvy (lotilaner) has ...